Specify a stock or a cryptocurrency in the search bar to get a summary
Abivax SA
ABVXABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France. Address: 7-11 boulevard Haussmann, Paris, France, 75009
Analytics
WallStreet Target Price
24.02 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ABVX
Dividend Analytics ABVX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ABVX
Stock Valuation ABVX
Financials ABVX
Results | 2019 | Dynamics |